{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:21:20Z","timestamp":1791462080178,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with peripheral arterial disease (PAD) are at increased risk for major adverse cardiovascular events (MACE) such as cardiovascular death, myocardial infarction, and stroke as well as major adverse limb events (MALE) such as amputation and acute limb ischemia. Therefore, prevention of thrombotic events is crucial to improve the prognosis of PAD patients. This review article concludes current evidence and guideline recommendations about antithrombotic therapy in PAD patients.<\/jats:p><jats:p>Antithrombotic therapy is highly effective to reduce MACE and MALE events in PAD patients. Recently, the concept of dual pathway inhibition (low-dose rivaroxaban plus acetylic salicylic acid (ASA) has been tested in the COMPASS and VOYAGER-PAD trial. Compared to ASA alone dual pathway inhibition was superior to prevent MACE and MALE. After peripheral revascularization, in particular the risk for acute limb ischemia was reduced. In contrast, the risk for major bleeding is increased. Therefore, current guidelines recommend the combination of low-dose rivaroxaban and ASA in PAD patients with low bleeding risk. In patients with high bleeding risk, a single antiplatelet drug (preferable clopidogrel) is indicated. In patients with atherosclerotic vascular disease and indication for oral anticoagulation, no additional antiplatelet drug is necessary, as this would increase the risk of bleeding without improving the prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antithrombotic treatment reduces MACE and MALE and is recommended in all patients with PAD. Individual bleeding risk should always be considered based on the current data situation and an individual benefit-risk assessment must be carried out.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.927645","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:12:50Z","timestamp":1665637970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Antithrombotic therapy in peripheral arterial disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Christine","family":"Espinola-Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Wei\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schwaderlapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Munzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence, and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper, and lower extremity arteries","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e009584","DOI":"10.1161\/CIRCINTERVENTIONS.120.009584","article-title":"Contemporary review of antithrombotic therapy in peripheral artery disease","volume":"13","author":"Hess","year":"2020","journal-title":"Circ Cardiovasc Interv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral arterial disease","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jacc.2018.06.041","article-title":"Major adverse limb events and 1-year outcomes after peripheral artery revascularization","volume":"72","author":"Hess","year":"2018","journal-title":"JACC."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1177\/2047487319846999","article-title":"Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery","volume":"26","author":"Venermo","year":"2019","journal-title":"Eur J Prev Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1724-4922","article-title":"When and how to combine antiplatelet and anticoagulant drugs?","volume":"42","author":"Espinola-Klein","year":"2022","journal-title":"H\u00e4mostaseologie."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE","year":"1996","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"EUCLID Trial Steering Committee and Investigators. Ticagrelor vs. clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA Trial","volume":"30","year":"2009","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy \u2013 the MIRROR study: a randomized double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxanban plus Aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD Trial","volume":"25","author":"Moll","year":"2018","journal-title":"J Endovasc Ther."},{"key":"B21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficiacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: A randomized trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure","volume":"28","author":"Sarac","year":"1998","journal-title":"J Vasc Surg."},{"key":"B23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"CASPAR writing committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials","volume":"29","author":"Anand","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and Aspirin in peripheral artery disease lower extremity revascularization. Impact of Concomitant Clopidogrel on Efficacy and Safety","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab390","article-title":"Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy","author":"Aboyans","year":"2020","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1024\/0301-1526\/a000834","article-title":"ESVM Guideline on peripheral arterial disease","volume":"48","author":"Frank","year":"2019","journal-title":"Vasa."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients","volume":"324","author":"Antithrombotic","year":"2002","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"TRA 2P\u2013TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"865166","DOI":"10.3389\/fcvm.2022.865166","article-title":"Differential inhibition of platelet reactivity by dual therapy with aspirin and low-dose rivaroxaban in peripheral arterial disease \u2013A pilot study","volume":"9","author":"Jurk","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo-controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.jacc.2014.03.039","article-title":"Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study","volume":"63","author":"Lamberts","year":"2014","journal-title":"JACC."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","article-title":"Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis","volume":"31","author":"Ducrocq","year":"2010","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.927645\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:12:55Z","timestamp":1665637975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.927645\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2022.927645"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.927645","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"927645"}}